Table 3.
Neuropsychological investigation of participants.
| Neuropsychiatric performance | Baseline | Endpoint | ||||||
|---|---|---|---|---|---|---|---|---|
| Probiotic | Placebo | Z | P | Probiotic | Placebo | Z | P | |
| HAMA | 13.83 (6.30) | 14.37 (6.34) | −0.453 | 0.65 | 9.54 (5.51) | 13.57 (6.16) | −2.997 | 0.003* |
| HAMD | 15.97 (6.03) | 16.60 (5.94) | −0.778 | 0.437 | 11.83 (5.49) | 15.23 (5.56) | −2.743 | 0.006* |
| QOLIE-89 | 48.91 (13.37) | 49.71 (13.64) | −0.006 | 0.995 | 60.29 (14.01) | 51.91 (13.20) | −2.758 | 0.006* |
“Z” indicates Mann Whitney U test. Bonferroni correction was applied to determine statistical significance. *p <0.008.